Niraparib for advanced solid tumors with DNA repair problems
Treatments studied
Part of Cancer clinical trials.
This trial tests if niraparib, a targeted therapy pill, can shrink advanced solid cancers that have specific DNA repair flaws (HRD). It's for people whose tumors have certain gene mutations or DNA damage signatures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have an advanced solid tumor that has spread or can't be removed with surgery.
- Your tumor must have a specific DNA repair problem (HRD) or mutations in HRR genes.
- You must be 19 or older.
- You must be willing to provide a tumor biopsy for testing.
- You cannot have had a PARP inhibitor before.
- You must not have active cancer in the brain or spinal cord lining.
- You must have measurable disease on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a second course of niraparib (a PARP inhibitor) after surgery for ovarian cancer that has come back in just a few spots. It aims to see if restarting niraparib can help keep the cancer from coming back again.
This Phase 1 study tests a combination of medicines (including niraparib and irinotecan) for advanced solid tumors that have specific DNA repair gene changes, such as BRCA1/2 or related defects. It aims to see whether the treatment can shrink tumors and is safe enough to continue studying.
This trial tests a drug called talazoparib (a PARP inhibitor) for advanced breast cancer that has a specific DNA repair defect (HRD) or a BRCA mutation. The goal is to see if the drug works better when the patient's tumor is tested for this defect just before treatment.
This trial studies talazoparib (a targeted pill) in people with advanced breast cancer whose tumors have problems repairing certain DNA damage. If your tumor has these specific “DNA repair” defects, the medicine may work better and stop the cancer from growing.
This trial tests a PARP-inhibitor medicine in people with advanced breast cancer who carry an inherited PALB2 gene change. It may help slow or shrink metastatic (spread) cancer after standard treatments have been tried.
This trial is testing a new drug (EIK1004) designed to block a protein called PARP1, which helps repair DNA. It is for people with advanced solid tumors, especially those with BRCA or other DNA repair gene mutations. The goal is to see if it can shrink tumors or slow their growth.
Hear when a new Efficacy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.